SecSonar.com

Denali Therapeutics Inc. (DNLI)

Denali Therapeutics Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Denali Therapeutics Inc. (DNLI) is a Biotechnology company based in US with a market capitalization of $3.4B. Free cash flow was negative at -$422.1M. This page tracks DNLI's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 443 employees · IPO Dec 8, 2017

Valuation

Valuation & price

$18.62 · as of May 17, 2026 · -27.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.31

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$25.57$19.16$12.75Jul 25Dec 25Jun 26Jul 7, 25$14.25Jul 9, 25$15.00Jul 11, 25$14.52Jul 15, 25$14.17Jul 17, 25$14.53Jul 21, 25$13.83Jul 23, 25$14.47Jul 25, 25$13.67Jul 29, 25$13.61Jul 31, 25$13.83Aug 4, 25$14.44Aug 6, 25$14.35Aug 8, 25$13.96Aug 12, 25$13.22Aug 14, 25$14.46Aug 18, 25$14.82Aug 20, 25$14.51Aug 22, 25$15.49Aug 26, 25$15.55Aug 28, 25$15.65Sep 3, 25$15.31Sep 5, 25$15.43Sep 9, 25$15.36Sep 11, 25$14.82Sep 15, 25$13.16Sep 17, 25$13.06Sep 19, 25$12.75Sep 23, 25$13.05Sep 25, 25$13.43Sep 29, 25$14.52Oct 1, 25$14.91Oct 3, 25$15.42Oct 7, 25$14.90Oct 9, 25$16.17Oct 13, 25$14.98Oct 15, 25$16.31Oct 17, 25$16.66Oct 21, 25$16.96Oct 23, 25$15.88Oct 27, 25$16.21Oct 30, 25$16.38Nov 3, 25$15.36Nov 5, 25$14.89Nov 7, 25$15.02Nov 11, 25$17.58Nov 13, 25$17.15Nov 17, 25$17.37Nov 19, 25$16.92Nov 21, 25$18.00Nov 25, 25$19.13Nov 28, 25$19.47Dec 2, 25$17.84Dec 4, 25$20.11Dec 8, 25$19.69Dec 10, 25$17.57Dec 12, 25$17.98Dec 16, 25$17.02Dec 18, 25$16.77Dec 22, 25$17.47Dec 24, 25$16.99Dec 29, 25$16.58Jan 2, 26$16.27Jan 6, 26$17.21Jan 8, 26$17.07Jan 12, 26$17.95Jan 14, 26$18.27Jan 16, 26$17.99Jan 21, 26$18.60Jan 23, 26$20.25Jan 27, 26$21.25Jan 29, 26$21.59Feb 2, 26$22.74Feb 4, 26$21.28Feb 6, 26$21.08Feb 10, 26$19.82Feb 12, 26$19.18Feb 17, 26$19.28Feb 19, 26$20.24Feb 23, 26$20.86Feb 25, 26$22.29Mar 2, 26$21.00Mar 4, 26$20.37Mar 6, 26$19.69Mar 10, 26$21.43Mar 12, 26$20.70Mar 16, 26$20.57Mar 18, 26$20.06Mar 20, 26$20.17Mar 24, 26$20.97Mar 26, 26$19.74Mar 30, 26$18.08Apr 1, 26$19.68Apr 6, 26$19.38Apr 8, 26$19.62Apr 10, 26$19.23Apr 14, 26$20.16Apr 16, 26$20.71Apr 20, 26$20.54Apr 22, 26$20.25Apr 24, 26$19.87Apr 28, 26$20.06May 1, 26$18.30May 5, 26$18.92May 7, 26$19.71May 11, 26$19.67May 13, 26$19.80May 15, 26$18.62May 19, 26$18.11May 21, 26$19.30May 26, 26$19.38May 28, 26$20.95Jun 1, 26$20.41Jun 3, 26$19.66Jun 5, 26$19.52Jun 9, 26$20.79Jun 11, 26$21.02Jun 15, 26$22.22Jun 17, 26$23.49Jun 22, 26$24.05Jun 26, 26$25.57
$12.7552-week range$25.57
Loading valuation history…

Fundamentals

Key fundamentals

$3.4B

Market cap

—

Revenue growth (YoY)

100.0%

Gross margin

-$422.1M

Free cash flow (USD)

-$825.6M

Net debt

Net cash position

6.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$129.2MFY 2019$26.7MFY 2020$335.7MFY 2021$48.7MFY 2022$108.5MFY 2023$330.5MFY 2024$0.00FY 2025$0.00
$0$0

Free cash flow by year

2016 → 2025

FY 2016$-78.5MFY 2017$-79.5MFY 2018$46.7MFY 2019$-169.5MFY 2020$413.1MFY 2021$-219.9MFY 2022$-262.5MFY 2023$-370.9MFY 2024$-363.6MFY 2025$-422.1M
-$78.5M-$422.1M

Gross margin by year

2021 → 2023

FY 2021100.0%FY 2022100.0%FY 2023100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAsset Sale AgreementJun 18, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 4, 2026Filing
  • 8-K eventStudy Results AnnouncementMay 22, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventCollaboration Agreement TerminationApr 3, 2026Filing
  • 8-K eventRoyalty Agreement FundingMar 31, 2026Filing

Questions

Frequently asked questions

What is Denali Therapeutics Inc.'s market cap?

Denali Therapeutics Inc. (DNLI) has a market capitalization of $3.4B.

What is DNLI's P/E ratio?

A meaningful P/E ratio is not available for DNLI — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is DNLI's price-to-book (P/B) ratio?

DNLI trades at 3.31 times book value per share.

Are insiders buying DNLI stock?

SEC Form 4 filings show no open-market insider buys at Denali Therapeutics Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

BEAM

Beam Therapeutics Inc.

$3.4B

TLX

Telix Pharmaceuticals Limited

$3.2B

KNSA

Kiniksa Pharmaceuticals, Ltd.

$3.7B

ACAD

ACADIA Pharmaceuticals Inc.

$3.7B

CRNX

Crinetics Pharmaceuticals, Inc.

$3.7B

VCYT

Veracyte, Inc.

$3.8B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.